TY - JOUR
T1 - The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands
AU - Al Khayat, Mohamed N M T
AU - Eijsink, Job F H
AU - Postma, Maarten J
AU - Wilschut, Jan C
AU - van Hulst, Marinus
PY - 2020/9
Y1 - 2020/9
N2 - OBJECTIVE: We aimed to assess the cost-effectiveness of hepatitis C virus (HCV) screening strategies among recently arrived migrants in the Netherlands.METHODS: A Markov model was used to estimate the health effects and costs of HCV screening from the healthcare perspective. A cohort of 50,000 recently arrived migrants was used. In this cohort, three HCV screening strategies were evaluated: (i) no screening, (ii) screening of migrants from HCV-endemic countries and (iii) screening of all migrants.RESULTS: Strategy (ii) screening of migrants from HCV-endemic countries compared to strategy (i) no screening, yielded an incremental cost-effectiveness ratio (ICER) of €971 per quality-adjusted life-years (QALYs) gained. Strategy (iii) screening of all migrants compared with strategy (ii) screening of migrants from HCV-endemic countries yielded an ICER of €1005 per QALY gained. The budget impact of strategy (ii) screening of migrants from HCV-endemic countries and strategy (iii) screening of all migrants was €13,752,039 and €20,786,683, respectively.CONCLUSION: HCV screening is cost-effective. However, the budget impact may have a strong influence on decision making.
AB - OBJECTIVE: We aimed to assess the cost-effectiveness of hepatitis C virus (HCV) screening strategies among recently arrived migrants in the Netherlands.METHODS: A Markov model was used to estimate the health effects and costs of HCV screening from the healthcare perspective. A cohort of 50,000 recently arrived migrants was used. In this cohort, three HCV screening strategies were evaluated: (i) no screening, (ii) screening of migrants from HCV-endemic countries and (iii) screening of all migrants.RESULTS: Strategy (ii) screening of migrants from HCV-endemic countries compared to strategy (i) no screening, yielded an incremental cost-effectiveness ratio (ICER) of €971 per quality-adjusted life-years (QALYs) gained. Strategy (iii) screening of all migrants compared with strategy (ii) screening of migrants from HCV-endemic countries yielded an ICER of €1005 per QALY gained. The budget impact of strategy (ii) screening of migrants from HCV-endemic countries and strategy (iii) screening of all migrants was €13,752,039 and €20,786,683, respectively.CONCLUSION: HCV screening is cost-effective. However, the budget impact may have a strong influence on decision making.
KW - Cost-Benefit Analysis
KW - Hepacivirus
KW - Hepatitis C/diagnosis
KW - Humans
KW - Markov Chains
KW - Mass Screening
KW - Netherlands
KW - Quality-Adjusted Life Years
KW - Transients and Migrants
U2 - 10.3390/ijerph17176091
DO - 10.3390/ijerph17176091
M3 - Article
C2 - 32825680
SN - 1661-7827
VL - 17
SP - 1
EP - 13
JO - International Journal of Environmental Research and Public Health
JF - International Journal of Environmental Research and Public Health
IS - 17
M1 - 6091
ER -